Table 1.
Patient and treatment characteristics.
| Characteristic | n (%) |
|---|---|
| Age (years) (median (range)) | 44.0 (32–57) |
| Race/Ethnicity | |
| Asian | 1 (8.3%) |
| Black | 1 (8.3%) |
| Hispanic White | 1 (8.3%) |
| Non-Hispanic White | 9 (75.0%) |
| KPS | |
| 90 | 7 (58.3%) |
| 100 | 5 (41.7%) |
| Menopausal Status at Diagnosis | |
| Post | 1 (8.3%) |
| Pre | 11 (91.7%) |
| Stage at Diagnosis | |
| II | 5 (41.7%) |
| III | 1 (8.3%) |
| IV | 5 (41.7%) |
| Unknown (III or Less) | 1 (8.3%) |
| ER/PR | |
| −/− | 2 (16.7%) |
| +/− | 2 (16.7%) |
| +/+ | 8 (66.7%) |
| HER2 | |
| − | 8 (66.7%) |
| + | 4 (33.3%) |
| Induction therapy * | |
| Taxane | 10 (83.3%) |
| Anthracycline | 4 (33.3%) |
| Alkylating Agent | 5 (41.7%) |
| Antimetabolite | 1 (8.3%) |
| Antihormone | 5 (41.7%) |
| Other | 5 (41.7%) |
| Time from initial diagnosis to diagnosis of metastasis (months) (median (range)) | 11.9 (0.0–98.5) |
| Time from initial diagnosis to protocol treatment (months) (median (range)) | 20.3 (5.5–103.1) |
| Time from diagnosis of metastasis to protocol treatment (months) (median (range)) | 6.7 (3.5–12.7) |
| Conditioning regimen | |
| Melphalan alone | 3 (25.0%) |
| Melphalan + STAMP | 9 (75.0%) |
| Radiation dose (EQD2, Gy) (median (range)) | 41.2 (37.9–48.7) |
| Number of metastatic sites treated | |
| 1 | 9 (75.0%) |
| 2 | 2 (16.7%) |
| 3 | 1 (8.3%) |
| Oligometastatic site | |
| Bone | 13 (81.3%) |
| Liver | 1 (6.3%) |
| Thoracic lymph node | 2 (12.5%) |
Abbreviations: KPS, Karnofsky performance status; ER, estrogen receptor; PR progesterone receptor; HER2, human epidermal growth factor receptor 2; Gy, Gray; carboplatin, thiotepa, and cyclophosphamide, STAMP; EGD2, equivalent dose in 2 Gy fractions. * In addition to standard adjuvant antiestrogen or HER2-directed therapy.